GlobalData on MSN
Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn
Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn. One of America’s ...
Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...
Irving-based Kimberly-Clark snaps up Tylenol maker Kenvue in a cash-and-stock blockbuster, uniting Kleenex, Huggies, and Band ...
The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...
The merger will bring together brands such as Huggies, Kleenex, Aveeno, and Tylenol, with Kimberly-Clark shareholders set to ...
11hon MSN
Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy
A £30 billion takeover shakes up the consumer health sector as Kimberly-Clark, the maker of Huggies nappies, prepares to ...
22hon MSN
Tylenol, Kleenex, Band-Aid and More Put Under One Roof in $48.7 Billion Consumer Brands Deal
Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company ...
Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?
The Manila Times on MSN
Kimberly-Clark to buy Tylenol maker Kenvue in $48.7-B deal
KIMBERLY-CLARK is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54 ...
Evercore also said Kimberly’s move expands its footprint into two stable, cash-generative global categories, personal hygiene and consumer health, that have high barriers to entry and rational pricing ...
The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...
Clark’s stock continued for a second day and raised the prospect that an activist investor could surface and try to block its merger-of-equals deal with Tylenol maker Kenvue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results